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Oral ivermectin is a safe broad spectrum anthelminthic used for treating several neglected
tropical diseases (NTDs). Currently, ivermectin use is contraindicated in children weighing
less than 15 kg, restricting access to this drug for the treatment of NTDs. Here we provide
an updated systematic review of the literature and we conducted an individual-level patient
data (IPD) meta-analysis describing the safety of ivermectin in children weighing less than
15 kg.
Methodology/Principal findings
A systematic review was conducted using the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) for IPD guidelines by searching MEDLINE via
PubMed, Web of Science, Ovid Embase, LILACS, Cochrane Database of Systematic
Reviews, TOXLINE for all clinical trials, case series, case reports, and database entries for
reports on the use of ivermectin in children weighing less than 15 kg that were published
between 1 January 1980 to 25 October 2019. The protocol was registered in the Interna-
tional Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515. A
total of 3,730 publications were identified, 97 were selected for potential inclusion, but only
17 sources describing 15 studies met the minimum criteria which consisted of known
weights of children less than 15 kg linked to possible adverse events, and provided compre-
hensive IPD. A total of 1,088 children weighing less than 15 kg were administered oral iver-
mectin for one of the following indications: scabies, mass drug administration for scabies
control, crusted scabies, cutaneous larva migrans, myiasis, pthiriasis, strongyloidiasis, tri-
churiasis, and parasitic disease of unknown origin. Overall a total of 1.4% (15/1,088) of chil-
dren experienced 18 adverse events all of which were mild and self-limiting. No serious
adverse events were reported.
Conclusions/Significance
Existing limited data suggest that oral ivermectin in children weighing less than 15 kilograms
is safe. Data from well-designed clinical trials are needed to provide further assurance.
Author summary
Oral ivermectin is a safe and efficacious drug for the treatment of neglected tropical dis-
eases. To date, ivermectin is not indicated in children weighing less than 15 kg because
there have been insufficient safety data to support a change of recommendation. A
PRISMA-level systematic review was conducted, and 97 potential sources were identified.
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All lead investigators were contacted to share individual patient data if they could provide
the minimum criteria. These were the known weights of the children less than 15 kg in
whom there were possible adverse events. A total of 17 investigators replied, sharing indi-
vidual-level patient data (IPD) from 15 studies, which represent a database of 1,088 chil-
dren weighing less than 15 kg treated with oral ivermectin. Overall 18 adverse events were
reported in 1.4% (15/1,088) of children, all of which were mild and self-limiting. No seri-
ous adverse events were recorded. These data suggest that ivermectin is safe for use in chil-
dren weighing less than 15 kilograms. Further data from well-designed clinical trials are
needed to assess the safety of oral ivermectin at escalating doses in children weighing less
than 15 kg.
Introduction
Ivermectin is a safe broad-spectrum anthelminthic drug registered for the treatment of several
neglected tropical diseases (NTDs) including onchocerciasis, lymphatic filariasis, scabies, and
strongyloidiasis. These NTDs frequently afflict small children but ivermectin is not currently
indicated or licensed for use in children weighing less than 15 kg because of a lack of safety evi-
dence. Because of this contraindication, alternatives to oral ivermectin are used in children
weighing less than 15 kg that may be less effective (e.g. topical creams for scabies) or potentially
toxic (e.g. lindane for scabies, thiabendazole for strongyloidiasis).
Ivermectin was developed initially for human use in the control of Onchocerca volvulus
transmission because it kills microfilariae rapidly and it inhibits release of microfilariae from
the gravid female worms. It is unlikely that infants and young children contribute substantially
to the transmission of O. volvulus because of the biology of the parasite; it takes more than one
year from entry of L3 larvae into the human body for these larvae to mature, find a mate,
become fertile, and start releasing microfilariae [1,2]. Field evaluations indicate that it is very
uncommon for children aged less than 5 years to be microfilaridermic [1,3]. Therefore, during
drug development, it was not considered necessary to evaluate the safety and efficacy of iver-
mectin in children weighing less than 15 kg for inclusion in mass drug administrations
(MDAs) for onchocerciasis control.
While there is a contraindication on the ivermectin package insert for treating children
weighing less than 15 kg, it is likely that there have been millions of children weighing less
than 15 kg who have been given ivermectin during MDA campaigns for onchocerciasis and
lymphatic filariasis in Africa. Over 400 million people were treated with ivermectin during
MDAs in 2019 alone, primarily in Africa, with over four billion treatments administered via
MDA to date [4]. To expedite ivermectin delivery during MDAs, ivermectin dosing is usually
based on height and not weight [5] with a cut-off for administration of 90 cm [4]. Based on
WHO Child Growth Standards, the median weight for a 90 cm child is 12.7 kg for boys and
12.5 kg for girls, thus a 90 cm child weighing 15kg would be on the 97th weight percentile for
boys and the 98th percentile for girls [6]. Therefore, it is likely that children with a weight
between 11 and 15 kg in practice are routinely administered ivermectin during MDAs. As
NTDs may cause growth stunting in children, for example infection with soil-transmitted hel-
minths (STHs) or onchocerciasis-associated Nakalanga syndrome [7] some children do not
reach 90 cm until they are older, and thus are denied ivermectin during MDA campaigns
which could eliminate the very parasites causing their stunted growth. Infants one to three
months of age have been treated with oral ivermectin (200 μg/kg) for scabies, with one dose
[8,9], or two doses spaced one to two weeks apart [9,10], with no neurological events reported.
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In mammals, ivermectin is prevented from crossing the blood brain barrier (BBB) by active
efflux via P-glycoprotein (P-gp) at the luminal membrane of capillary endothelial cells [11].
However, neurotoxic complications have been observed in certain dog breeds (e.g. Collies,
Sheepdogs) following ivermectin treatment. It was discovered that these dog breeds have a
four base pair deletion in the ABCB1 gene [12] that causes complete loss of transport function
of P-gp allowing entry of ivermectin into the central nervous system [13]. A recent case report
illustrates that nonsense mutations in the ABCB1 gene leading to a loss of function of P-gp
associated with a neurological adverse event in a 13-year-old boy following a single dose of
ivermectin (200 μg/kg) [14]. Concerns have been raised regarding the use of ivermectin in
infants due to a partially formed BBB.
During early drug development, preclinical toxicity studies of ivermectin were performed
in neonatal rats and macaques. Neurotoxicity was observed in 1- to 2- day old rats (CRCD
strain), which manifested as ataxia, ptosis, and decreased activity. The rat neonatal LD50 was
2.3 mg/kg, approximately twenty-fold lower than the adult LD50 of 42.8–52.8 mg/kg [15].
However, neonatal rats may not be an ideal model for ivermectin toxicity for human infants.
In general, human and primate BBB development begins earlier in gestation and proceeds
more rapidly than it does in rodents [16]. By birth, the ratio of human P-gp expression of new-
borns to adults is higher in humans [17] compared to rats [18]. Neonatal macaques are a better
model for humans. Macaques aged 6–13 days old given oral ivermectin (100 μg/kg) for 14 days
experienced no AEs [15]. In humans, P-gp reaches adult levels of expression three to six
months after birth [16].
A systematic review of the safety of oral ivermectin in small children published previously
[19], concluded that the limited available literature suggests that ivermectin is well tolerated by
small children with no serious or long-term adverse effects. Here we provide an updated and
more detailed review of the published literature on the safety of ivermectin in children weigh-
ing less than 15 kg using individual-level patient data (IPD).
Methods
Ethics statement
Data included in this analysis were obtained in accordance with ethical approvals from the loca-
tion of origin. Data were requested to be shared anonymized. A non-human subjects use proto-
col was established for the acquisition of IPD, reviewed by the Walter Reed Army Institute of
Research (WRAIR#2458). Consent was not obtained because data were analyzed anonymously.
Literature review
Reports on the use of ivermectin in children weighing less than 15 kg were searched for on the
following databases: MEDLINE via PubMed, Web of Science, Ovid Embase, LILACS,
Cochrane Database of Systematic Reviews, TOXLINE, and ClinicalTrials.gov. Databases were
searched in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses of individual participant data (PRISMA) statement (S1 Checklist) [20]. Clinical trials,
case series, case reports, and database entries published between 1 January 1980 to 25 October
2019 in any language describing ivermectin use in small children were identified. The US
Food and Drug Administration, the Australian Adverse Drug Reactions Advisory Committee,
the EudraVigilance system, and Vigibase (maintained by the WHO Collaborating Centre for
International Drug Monitoring) were contacted for case reports of ivermectin adverse reac-
tions in children weighing less than 15 kg however, these databases do not collect weights of
individuals so no data could be contributed to this study. The protocol was registered in the
International Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515.
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Three independent investigators undertook the review process and extracted the data (PJ,
WM, KCK), resolving discrepancy through discussion. Search terms included but were not
restricted to: (soolantra OR sklice OR oramec OR mk933 OR "mk 933" OR ivomec OR eqvalan
OR eqvalen OR epimer OR diapec OR cardomec OR stromectol OR mectizan OR ivermectin)
AND (child or children OR newborn� OR infan� or new-born� or perinat� or neonat� or
baby� or babies or toddler� or boy or boys or girl or girls or kid or kids or pediatric� or
paediatric� or peadiatric� or prematur� or preterm� OR "low birth weight" or vlbw or lbw or
preschool�). Screening was based on the title and abstract, and if treatment based on age (�5
years old) or weight (<15 kg) was not clearly defined, then a review of the manuscript was per-
formed. To confirm if ivermectin was used in children weighing less than 15 kg, authors of
possible reports of ivermectin use in small children were contacted via email on at least 3
attempts in English, and when warranted in French, Portuguese, Spanish, or Swedish. In some
cases, attempts were made to call and/or message authors via ResearchGate.
Lead investigators of identified studies were contacted to share individual-level patient data
IPD. Only studies including weight of ivermectin-treated children less than 15 kg and adverse
events data were considered for the final IPD meta-analysis. Adverse events were defined as
the appearance or worsening of any undesirable sign, symptom, or medical condition after
starting the study drug, even if the event was not considered related to the study drug. Serious
Adverse Events (SAEs) were defined as any untoward medical occurrence that at any dose:
resulted in death; was life-threatening; required inpatient hospitalization or resulted in pro-
longation of existing hospitalization; resulted in persistent or significant disability/incapacity;
was a congenital anomaly/birth defect; or was a medically important event or reaction [21].
Additional patient-level data including disease indication for ivermectin use, manufacturer,
brand name, dose, regimen, and delivery method were requested. IPD shared with the World-
Wide Antimalarial Resistance Network (WWARN) were curated and standardized as
described in a data management plan [22]. Any data inconsistencies or missing information
were resolved directly with the investigators. Descriptive summaries were made to describe the
risk of selection bias and reporting bias from the IPD contributing studies.
Outcome
The primary outcome was the incidence of adverse events in children weighing less than 15 kg
that ingested oral ivermectin.
Statistical analysis
Since data were limited and heterogenous, mostly descriptive analyses were conducted. Inci-
dences of AEs, their grading and causality classification, as determined by the on-site principal
investigator or physician in each study were pooled and analyzed. Incidence of any AEs in chil-
dren weighing less than 15 kg who were treated for scabies was estimated by pooling data from
cohort, MDA or randomized studies (excluding case reports/series) using fixed logistic regres-
sion model (stata command metapreg). Heterogeneity between studies was quantified using I2
measure. Exact confidence intervals are presented for individual studies and for rate of SAE.
Risk of bias was assessed based on study design and AE elicitation method.
Results
Systematic review summary
A total of 3,730 potential publications were identified and assessed for eligibility from literature
database searches, of which 97 were selected for potential inclusion in the review (Fig 1). We
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attempted to contact all authors of the publications, and received responses for only 59.8%
(58/97) of publications. Of responding authors, 29.3% (17/58) successfully provided IPD on
ivermectin use in children weighing less than 15 kg, while 31.0% (18/58) confirmed that oral
ivermectin was not provided to children weighing less than 15 kg, 8.6% (5/58) reported they
no longer had access to the data, 6.9% (4/58) reported that ivermectin was used in children
weighing less than 15 kg but weight or adverse event data were not recorded or were not avail-
able, 22.4% (13/58) reported they used ivermectin in children weighing less than 15 kg but
failed to provide the IPD data, and 1.7% (1/58) reported that children weighing less than 15 kg
will be treated with oral ivermectin but the study has not started yet (S1 Table). Overall,
Fig 1. PRISMA IPD flow diagram. Fig 1 depicts the total number of studies identified from systematic review, rationale for
exclusion, and number of studies included in the final analyses. � See S1 Table for list of studies and rationale for inclusion or
exclusion from the review.
https://doi.org/10.1371/journal.pntd.0009144.g001
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17 reports describing 15 studies provided IPD. Characteristics of the 15 included studies are
summarized in Table 1. Study designs utilized include: case reports 46.7% (7/15; 10 subjects),
case series 26.7% (4/15; 175 subjects), cohort studies 6.7% (1/15; 4 subjects), MDA 6.7% (1/15;
838 subjects), a prospective observational study 6.7% (1/15; 17 subjects), and a randomized
controlled trial 6.7% (1/15; 44 subjects). No issues were identified in IPD integrity.
IPD summary
From the 17 reports, there were 1,088 confirmed instances in which oral ivermectin was given
to children weighing less than 15 kg. The majority of the treated children (80.2%, 867/1,081)
were younger than five years of age with an overall median age of 36 months (range 1–132
months). Median weight was 13.0 kg (range 4.0–14.9 kg). Height was only available in 5 out of
15 studies, for 10.9% (119/1,088) of children, with a median of 84 cm (range 54–103 cm) and
28.6% (34/119) were 90 cm or taller.
Of ivermectin-treated children, 82.8% (901/1,088) received two doses of ivermectin any-
where from 1 to 19 days apart. Although 200 μg/kg of ivermectin is the standard oral dose for
most NTDs, 86.5% (941/1,088) children received a dose between 201–300 μg/kg and 1.7% (19/
1,088) received doses above 300 μg/kg (Fig 2). Overall, the median dose administered was
221 μg/kg (range 81–556 μg/kg). The doses administered were significantly higher in the two-
dose regimen (median 231 μg/kg, range 94–556, n = 901) compared to the single-dose regimen
(median 214 μg/kg, range 81–500 μg/kg, n = 187), (p<0.001, Mann Whitney test).
Oral ivermectin was administered to children weighing less than 15 kg for a total of nine
indications including: scabies MDA 77.0% (838/1,088), scabies individual treatment 17.3%
(188/1,088), trichuriasis 4.0% (44/1,088), strongyloidiasis 0.8% (9/1,088), cutaneous larva
migrans 0.4% (4/1,088), crusted scabies 0.2% (2/1,088), myiasis 0.1% (1/1,088), pthiriasis 0.1%
(1/1,088), and parasitic disease of unknown origin 0.1% (1/1,088). Instances of ivermectin
administration to children weighing less than 15 kg were reported from ten countries includ-
ing: Solomon Islands 77.0% (838/1,088), France 17.4% (189/1,088), Côte d’Ivoire 4.0% (44/
1,088), Mexico 0.5% (5/1,088), Cambodia 0.4% (4/1,088), Spain 0.4% (4/1,088), Brazil 0.1% (1/
1,088), Guadeloupe 0.1% (1/1,088), Peru 0.1% (1/1,088), and Venezuela 0.1% (1/1,088).
In total, 18 AEs were reported from 1.4% (15/1,088) of ivermectin-treated children and
none of the AEs (0/18, 95%CI 0–0.33%) were deemed SAEs (Table 2). The most common AEs
reported were diarrhea 0.4% (4/1,088) and eczema 0.5% (5/1,088). Headache, itching and
vomiting were each reported twice 0.2% (2/1,088) and joint pain, abdominal pain, and sym-
metrical edema of the feet were each reported once 0.1% (1/1,088) (Tables 2 and S2). Twelve
patients reported only one AE, while three patients reported 2 AEs: headache and diarrhea
(n = 1), abdominal pain and vomiting (n = 1), diarrhea and itching (n = 1). All AEs were
deemed possibly related to ivermectin administration, except for the joint pain which was clas-
sified as unlikely related to ivermectin administration. Adverse events were related to scabies
treatment or MDA for scabies in 50% (9/18), trichuriasis in 44.4% (8/18), and strongyloidiasis
in 5.6% (1/18) of patients. A pooled prevalence of AEs in the scabies, crusted scabies, or scabies
MDA data derived from 3 studies, was estimated as 0.88% (95%CI 0.48–1.68) (Table 3). Seven
of the AEs occurred in children that were co-administered either topical creams for scabies (4/
7), oral azithromycin (2/7), or intravenous iron plus vitamin supplements (1/7) (Table 2). No
adverse events were reported in the 1.3% (14/1,081) of children three months or younger. Of
128 children who received�200 μg/kg ivermectin, 7.0% (9/128) experienced an AE, of 960
children who received>200 μg/kg ivermectin 0.6% (6/960) reported an AE, and of 19 children
who received>300 μg/kg ivermectin none reported an AE. All AEs were considered mild,
self-limiting, and resolved without further intervention.
PLOS NEGLECTED TROPICAL DISEASES Ivermectin safety in children less than 15 kg





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLOS NEGLECTED TROPICAL DISEASES Ivermectin safety in children less than 15 kg













































































































































































































































































































































































































































































































































































































































































































































































































































PLOS NEGLECTED TROPICAL DISEASES Ivermectin safety in children less than 15 kg
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009144 March 17, 2021 9 / 22
Risk of bias
A single patient case report or small case series does not allow for estimation of AE frequency,
but provides descriptive or narrative results. Therefore, case reports or case series in our review
(study IDs 2–11,17) [8,23–32] with patients (n = 16) seen in the clinic were categorized as high
risk of selection and reporting bias.
Fig 2. Ivermectin dose and number administered to children weighing less than 15 kg. Fig 2 depicts the ivermectin
dose administered in μg/kg (inner ring) and the number of doses administered (outer ring) that were collected for the
IPD database (n = 1,088).
https://doi.org/10.1371/journal.pntd.0009144.g002





















1 1 11 Diarrhea Possible 10 10 10 2 300 Scabies Topical Cream
2 2 13 Diarrhea Possible 1 10 24 1 100 Trichuriasis
3 3 13 Diarrhea Possible 3 11 24 1 182 Trichuriasis
4 4 12 Diarrhea Possible 8 13 24 2 231 Scabies MDA Azithromycin
5 5 11 Eczema Possible 10 10 12 2 150 Scabies
6 6 11 Eczema Possible 7 10 16 2 200 Scabies Topical Cream
7 7 11 Eczema Possible 10 10 18 2 150 Scabies Topical Cream
8 8 11 Eczema Possible 8 10.1 14 2 297 Scabies Topical Cream
9 9 11 Eczema Possible 8 11 31 2 205 Scabies
10 2 13 Headache Possible 1 10 24 1 100 Trichuriasis
11 10 13 Headache Possible 1 13 60 1 192 Trichuriasis
12 3 13 Itching Possible 3 11 24 1 182 Trichuriasis
13 11 13 Itching Possible 1 13.2 24 1 114 Trichuriasis
14 12 12 Joint Pain Unlikely 8 13 36 2 231 Scabies MDA Azithromycin
15 13 13 Abdominal Pain Possible 1 14 60 1 107 Trichuriasis
16 14 11 Vomiting Possible 10 11 32 2 273 Scabies
17 13 13 Vomiting Possible 3 14 60 1 107 Trichuriasis
18 15 4 Symmetrical
Edema of the Feet
Possible 1 4.7 18 2 200 Strongyloidiasis IV Iron and Vitamin
Supplement
AE, adverse event; IVM, ivermectin; kg, kilograms; mo, months; IV, intravenous
https://doi.org/10.1371/journal.pntd.0009144.t002
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Among the remaining studies, low risk of selection bias is expected in the randomized con-
trol study (study ID 14) [33] (n = 44) and the MDA trial (study ID 13) [34] in which all eligible
persons in the study area were treated (n = 838) and participants from randomly selected vil-
lages were followed up for AEs, and moderate risk in the prospective studies (study IDs
1,15,16) [35–37] (n = 21). Only two studies actively asked for AEs (study ID 12,14) [9,33]
(n = 213), while MDA (study ID 13) [34] (n = 838) and cohort studies (study ID 15,16) [35,36]
(n = 4) used passive reporting of AEs, and were categorized a high risk for reporting bias.
One study identified by the review [10] could not be included in the analysis because AEs
were not linked to individual patients. The article reported that among 15 children weigh-
ing<15kg treated for scabies, two experienced AEs (one was nervous and irritable and the
other scratched intensely). Including this study would slightly increase the pooled AE fre-
quency to 1.06% (95% CI 0.59–1.90%) (Table 3). In any other studies (n = 79) for which IPD
could not be obtained, data published could not be used in the synthesis as the AEs and num-
ber of patients studied were not presented explicitly in the weight group of interest. Conse-
quently, we cannot assess representativeness of the IPD collated in relation to all ivermectin
use data available in this weight group.
Discussion
This systematic review identified 97 reports where ivermectin was potentially used in children
weighing less than 15 kg for numerous indications including: scabies MDA, scabies, crusted
scabies, strongyloidiasis, onchocerciasis, lymphatic filariasis, baylisascariasis, head lice, pubic
lice, cutaneous larva migrans, gnathostomiasis, trichuriasis, tungiasis, trombidiasis, rosacea,
capillariasis, myiasis, intestinal acariasis, and parasitic disease of unknown origin. However,
IPD reporting both the weight and adverse events could only be acquired from 17 reports,
accounting for 1,088 children, treating the following indications: scabies MDA, scabies,
crusted scabies, strongyloidiasis, pthiriasis, cutaneous larva migrans, trichuriasis, myiasis, and
parasitic disease of unknown origin (Table 1). The evidence summarized here indicates that
oral ivermectin caused AEs in 1.4% (15/1,088) children weighing less than 15 kg and there
were no SAEs reported. With a sample size of 1000, the probability of observing at least one
AE with prevalence of 1 in 1000 is 0.632, and>0.999 for adverse events with incidence 1 in
100. Thus, the upper 95% confidence interval for the true incidence of AEs following ivermec-
tin administration to children <15kg is 1 in 362.
All data contributors rated the AEs as being possibly caused by ivermectin treatment with
the exception of joint pain which was rated as unlikely to be caused by ivermectin. Of the reported
AEs, headache 2 (0.18%), vomiting 2 (0.18%), abdominal pain 1 (0.09%), diarrhea 4 (0.37%), and
itching 2 (0.18%) have all previously been described for ivermectin and in the current study
occurred at rates less than stated on ivermectin package inserts [38,39]. Our study results therefore
Table 3. Pooled AE incidence in children with Scabies, Crusted scabies, or participating in MDAs for scabies
(excluding case studies) from a fixed effects logistic regression model. I2 statistics (variation in log-odds attributable
to heterogeneity) = 21.4%.
Study ID Number of patients Number of AE AE incidence (%) 95% CI
1 17 0 0.00% 0.00% - 19.51%
12 169 7 4.14% 1.68% - 8.35%
13 838 2 0.24% 0.03% - 0.86%
Overall—Fixed Effects 0.88% 0.46% - 1.68%
Bécourt et al. 2013 15 2 13.33 1.66–40.46
Overall—Fixed Effects 1.06% 0.59% - 1.90%
https://doi.org/10.1371/journal.pntd.0009144.t003
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suggest that ivermectin is as safe and well-tolerated in children weighing less than 15 kg as indeed
it is for persons weighing more than 15 kg. One patient given oral ivermectin for strongyloidiasis
had symmetrical edema of the feet, but this could not be directly attributed to ivermectin because
the child was extremely malnourished and was also given intravenous fluids, iron, and supple-
ments [26]. A limitation of this study is the lack of responses from several authors 32.0% (31/97)
and inability to contribute IPD-level data after confirmation of oral ivermectin use in children
weighing less than 15 kg 13.4% (13/97) from published reports.
This evidence has been compiled into an IPD database, held at WWARN, and available
upon request to by contacting the study authors. Our hope is that this database can be used for
regulatory review regarding the safety of ivermectin in children weighing less than 15 kg.
These data can be difficult to compile as they are generated from a wide range of treatment
indications from around the world. The following sections discuss key issues surrounding use
of ivermectin in children weighing less than 15 kg.
Ivermectin treatment and mass drug administration for scabies
Several trials of ivermectin MDA for the control of scabies have been performed in the South
Pacific [34,40,41]. Adequate population coverage is critical for the success of scabies MDA.
The use of oral ivermectin has logistical and compliance advantages over topical creams. Fur-
thermore, MDA of oral ivermectin was found to be more effective than topical permethrin
[40]. Children not treated by ivermectin during MDA serve as a reservoir for future commu-
nity re-infection unless adequately treated with topical treatments. One MDA trial for scabies
in the Solomon Islands co-administered ivermectin and azithromycin for the control of scabies
and impetigo. Azithromycin is indicated for use in children weighing 12.5 kg or more, and in
the trial in the Solomon Islands the 12.5 kg limit was also used for ivermectin for pragmatic
reasons. A total of 838 children weighing 12.5 to less than 15 kg received ivermectin as part of
MDA, and only two adverse events were reported in this group [34].
In 2018, Ethiopia performed the largest scabies ivermectin MDA to date, treating 1,634,271
persons with oral ivermectin. Drug administration was not based on height or weight but by
age. Children two to six years old were administered a single 3 mg ivermectin tablet, with
147,380 children in this age range treated [42]. Based on WHO Child Growth Standards, the
median weight for a 24-month-old child is 12.2 kg for boys and 11.5 kg for girls, with children
achieving a median 15.0 kg weight at 40 months for boys and at 42 months for girls [6]. Enbiale
et al. report that roughly 30% of children aged two to six years old were given more costly and
logistically difficult to administer topical permethrin or sulfur creams instead of oral ivermectin,
which may have occurred because of confusion with onchocerciasis guidelines indicating that
children under five years of age should not be treated with ivermectin [42]. In this review, of the
children weighing less than 15 kg treated with oral ivermectin, 19.8% (214/1,081) were five
years of age or older. While this data set is limited, it suggests that treating by age with five years
old as a cutoff would still frequently provide ivermectin to children weighing less than 15 kg. Of
the children weighing less than 15 kg treated with oral ivermectin, 28.6% (34/119) were 90 cm
or taller. This illustrates that the 90 cm cutoff for ivermectin administration during MDAs
means that children weighing less than 15 kg are routinely treated with ivermectin. Establishing
the safety of ivermectin in children weighing less than 15 kg would remove the imprecise
weight, height, and age restriction barriers and facilitate more streamlined ivermectin MDAs.
Scabies is recognized in France as a common clinical problem, including in small children.
In 2014, the French Medicines Regulatory Agency “Agence Nationale de Sécurité du Médica-
ment”, published a decision algorithm for treatment of scabies in children aged less than one
year. This algorithm recommends treatment with two doses of oral ivermectin (200 μg/kg) one
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week apart in infants who fail scabies treatment with permethrin or benzyl benzoate topical
creams, or have a contraindication for topical esdepallethrin spray (e.g. asthma) [43]. A survey
of French dermatologists found that oral ivermectin was unlikely to be used in infants with
common scabies weighing less than 10 kg (15%). However, willingness to use oral ivermectin
in children weighing less than 10 kg increased: if the child had asthma (25%), after topical
cream failure (40%), complications with impetigo (60%), profuse scabies (70%), or if the child
was unlikely to be seen again follow-up (65%). Furthermore, survey respondents were willing
to treat scabies in children less than three months with oral ivermectin [44]. Indeed, in this
current review, of the 14 children that were three months or younger that were administered
oral ivermectin, all of them were treated for scabies and 92.9% (13/14) were treated in France.
France appears to be the first country with clear guidance to use oral ivermectin off-label for
treatment of scabies in children weighing less than 15 kg.
Ivermectin treatment for soil-transmitted helminthiasis and
strongyloidiasis
Ivermectin has been used for the treatment of young children weighing less than 15 kg with
infections due to STHs or Strongyloides stercoralis. The combination of ivermectin and alben-
dazole is superior to either drug alone for the treatment of Trichuris trichiura [45] and alben-
dazole is superior to ivermectin for the treatment of hookworm. The Global Program for the
Elimination of Lymphatic Filariasis (GPELF) co-administered ivermectin and albendazole to
52 million school-aged children via MDA in 2015 [46] and this combination has been added
to the WHO List of Essential Medicines for Children [47]. However, the combination is still
not used in children weighing less than 15 kg because of the ivermectin contraindication. Part
of the GPELF rationale for albendazole and ivermectin co-administration was increased sec-
ondary effects against STHs [48]. The triple-drug therapy of ivermectin, diethylcarbamazine,
and albendazole (IDA) was recently shown to be superior for the treatment of lymphatic filari-
asis [49] and Merck has pledged an additional 100 million ivermectin treatments annually to
use in triple-drug therapy IDA MDAs outside of Africa [50]. However, with the success of the
GPELF against lymphatic filariasis, MDA is now scaling back in many areas. If community-
wide MDA programs with ivermectin and albendazole are to continue in the future, then STH
programs will have to shift strategies from school-based administration of albendazole to com-
munity-wide MDAs with combinations of ivermectin and albendazole, and inclusion of chil-
dren weighing less than 15 kilograms could be considered.
A recent clinical trial demonstrated that ivermectin for T. trichiura infection is safe in pre-
school-aged children, some of whom weighed less than 15 kg (n = 44) [33], but safety studies
of the combination of ivermectin and albendazole in children weighing less than 15 kg are
lacking. STH infection at a young age is associated with growth stunting, impairment of cogni-
tive development, and reduced school attendance. Co-administration of ivermectin and alben-
dazole during MDAs to small children infected with STHs could positively impact childhood
development in many settings.
Expanding ivermectin use for children weighing less than 15 kg during MDAs could have
marked health benefits for this group through impact on S. stercoralis burden. Repeated annual
ivermectin MDA for onchocerciasis control in Colombia [51] and Ecuador [52] demonstrated
marked and sustained reductions in S. stercoralis prevalence. Three rounds of annual ivermec-
tin and albendazole MDA in Argentina [53] and two rounds of annual ivermectin MDA in
Australia [54] led to marked reduction on S. stercoralis prevalence. Strongyloidiasis can be life
threatening in small children and ivermectin is a safe and effective cure for infected children
weighing less than 15 kg [26,29,35,36,55].
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Ivermectin for myiasis
The administration of oral ivermectin for myiasis has proven to be effective as it prevents complica-
tions in surgery and reduces the difficulty of mechanical removal of the larvae [56]. Children are vul-
nerable to nasal [57], oral [57,58], ocular [59–61], and auricular myiasis [57,62]. Treatment of
children with oral ivermectin (200–350 μg/kg) for myiasis is effective [30,59–61,63] but use in chil-
dren weighing less than 15 kg has been extremely limited due to the current contraindication [38,39].
Onchocerciasis, onchocerciasis-associated epilepsy and Nodding Syndrome
While the prevalence of onchocerciasis microfilaridermia in children aged less than five years
is expected to be low, these children can become infected in areas of high O. volvulus transmis-
sion and present disease manifestations, especially pruritus [64]. The presence of troublesome
itching may produce general fatigue, insomnia, and distraction at school [65,66]. It is possible
that itching could be exacerbated in O. volvulus infected children weighing less than 15 kg that
were treated with ivermectin, however, no studies were identified that assessed ivermectin in
this weight class and disease combination. Trials in O. volvulus infected children weighing less
than 15 kg are recommended before large scale ivermectin MDA rollout in onchocerciasis
endemic regions in this weight class. In addition, the relative risk of excess mortality associated
with onchocerciasis is higher, for a given microfilarial load, for younger age groups [67]. Fur-
thermore, there is a consistent association between onchocerciasis and the incidence of oncho-
cerciasis-associated epilepsy and Nodding Syndrome when the infection is intense and occurs
at a very young age [68–73]. Nodding Syndrome, a form of epilepsy, may be caused by an auto-
immune reaction to O. volvulus infection [74] and afflicts children between three and 18 years
old [75]. Onchocerciasis-endemic regions where ivermectin MDAs are routinely performed
have reduced [76–79]. All of these observations suggest that inclusion of children weighing
less than 15 kg in ivermectin MDA will benefit child health in onchocerciasis endemic areas.
Ivermectin use for malaria control
Ivermectin has been proposed as a novel malaria control tool due to its ability to kill Anopheles
mosquitoes and ivermectin MDA can suppress Plasmodium transmission [80–82]. When
using ivermectin MDA as a malaria control agent, coverage is the most critical component of
efficacy [83]. The contraindication of ivermectin for children weighing less than 15 kg excludes
roughly 20% of the population in malaria endemic areas, potentially inhibiting MDA efficacy.
In Africa, children under five years old are frequently bitten by Anopheles as evidenced by high
rates of new malaria infections in this population [82]. Untreated small children serve an
important reservoir of Plasmodium and can facilitate onwards transmission to mosquitoes.
Clinical trials have evaluated the safety, and efficacy of ivermectin along with the antimalar-
ial drugs artemether-lumefantrine [84] and dihydroartemisinin-piperaquine [85,86] in adults.
However, safety data in children and infants are needed in order to expand administration of
these combinations to younger age groups. Currently in the African Sahel, seasonal malaria
chemoprophylaxis (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) is
given annually to 10–15 million children less than five years old, as an effective tool to reduce
clinical incidence of severe malaria. Combining ivermectin MDAs with SMC would simulta-
neously target the parasite and vector, likely further reducing malaria in young children [87].
Before ivermectin and SP-AQ can be co-administered, safety and efficacy studies should be
performed. Finally, ivermectin has been shown to inhibit liver-stage development of Plasmo-
dium berghei [88], but its prophylactic efficacy in humans is debatable. Field evidence of
repeated ivermectin (150 μg/kg) MDAs demonstrated that ivermectin treatment reduced the
likelihood of infection and number of P. falciparum clones per infection beyond predicted
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community-wide transmission benefit, suggestive of ivermectin liver-stage prophylactic effect
[82]. However, a recent controlled human malaria infection trial with single dose ivermectin
(400 μg/kg) in adults failed to prevent P. falciparum infection [89]. If ivermectin can indeed
inhibit Plasmodium development in treated humans, then this makes the inclusion of children
weighing less than 15 kg in ivermectin MDAs for malaria control even more critical as they
suffer a higher burden of morbidity and mortality from malaria.
Pediatric ivermectin formulations and dosage
Oral Ivermectin is typically delivered as 3 mg or 6 mg tablets, and while the 3 mg tablet size is
relatively small, 5.5 mm diameter for Stromectol (Merck & Co., Whitehouse Station, NJ,
USA), it can be difficult for young children to swallow oral tablets. Since there is no pediatric
ivermectin formulation available in France, the French Medicines Regulatory Agency recom-
mends to crush a whole 3 mg tablet for children weighing 10–15 kg or half of a three mg tablet
for children weighing less than 10 kg, mix thoroughly in 10 mL of water, and administer [43].
In the clinical setting, there was no evidence of children weighing less than 15 kg choking
when swallowing crushed ivermectin (3 mg) mixed in liquid (n = 169) [9]. A recent study
milled three mg tablets into smaller 0.5 mg minitablets to provide to children aged two to 12
years old, many of whom weighed less than 15 kg (n = 43) [33]. In Latin America, a liquid oral
formulation has been manufactured and used in several trials for treatment of young children
with head lice in Colombia [90–92], and specifically in infants weighing less than 15kg for
strongyloidiasis in Venezuela [26] and myiasis in Peru [30]. A liquid oral, minitablet, oro-dis-
persible minitablet, or multiparticulate formulation for small children would be advantageous
for use in clinical treatment and MDA settings. The considerations outlined in this manuscript
underline the need for the development of an adapted pediatric formulation of ivermectin.
The ideal dose of ivermectin for different indications in small children is not known. Available
data suggest that adult based dosing is not appropriate for children and that dose escalation effi-
cacy trials in children weighing less than 15 kg are needed. Recent pharmacokinetic analyses indi-
cate that ivermectin treated children aged less than 12 years reach half the peak concentration and
total exposure of adults [93] and a dose increase for young children was suggested [94]. A multi-
center analysis found that ivermectin was significantly more effective at treating scabies in chil-
dren weighing less than 15 kg when the dose was more than 200 μg/kg compared to less than
200 μg/kg [9]. This suggests that the standard 200 μg/kg dose of ivermectin may not reach effective
levels in small children for all NTDs. This review identified 939 children treated with 201–300 μg/
kg, 17 children treated with 301–400 μg/kg, and four children treated with>400 μg/kg. This lim-
ited evidence suggests that ivermectin doses greater>200 μg/kg are potentially safe and well toler-
ated in children weighing less than 15 kg. One limitation of this review is that most of the
evidence 92.6% (1,007/1,088) is derived from two studies, one MDA study in the Solomon Islands
[34] and a case series from France [9]. A multi-country, randomized, double-blind, placebo-con-
trolled, dose escalation (200, 400, 800 μg/kg) study, dubbed the Ivermectin Safety in Small Chil-
dren (ISSC) trial (NCT04332068) is currently underway, which is designed to assess the safety,
pharmacokinetics, and efficacy of oral ivermectin in scabies-infected children weighing less than
15 kg [95]. An additional concern to ivermectin dosing in children weighing less than 15 kg are
potential drug-drug interactions with other drugs frequently used in MDA populations (e.g. anti-
retrovirals) that may alter safety or pharmacokinetics.
A call for clarity in data reporting
Age is not a limiting criterion listed on most ivermectin package inserts but weight <15 kg
and/or height <90 cm when used in MDAs are directly contraindicated [38]. However, there
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is a common misconception reported in the literature that children aged less than five years
should not be administered ivermectin. Not treating children under five years of age would
further restrict ivermectin use, as these children frequently weigh 15 kg or more or are 90 cm
or taller [6]. Reports of ivermectin use in case studies, series, or trials frequently group subjects
by age rather than by weight, providing no conclusive evidence for ivermectin safety in chil-
dren weighing less than 15 kg. Of the 97 possible reports identified in this review, only four
stated the number of children weighing less than 15 kg that were administered oral ivermectin
[9,10,34,95]. Here we call for greater clarity when reporting ivermectin use in children to
include the weight of any child below 15 kg and reporting of any associated AEs to the individ-
ual-patient level. An IPD call for ivermectin safety in children weighing less than 15 kg has
been organized by WWARN and data from future publications or clarifications to publications
cited in S1 Table can be contributed by contacting the study authors.
Conclusion
Millions of children weighing less than 15 kg are currently denied access to ivermectin treat-
ment due to the current label indication. In order to remove this barrier and improve treat-
ment equity, further evidence in children weighing less than 15 kg must be gathered and
clearly compiled for review. The theoretical concern regarding the potential for neurotoxicity
of ivermectin in infancy has not been confirmed. This IPD meta-analysis provide new evi-
dence to be considered by medicines regulatory authorities and policy makers regarding the
safety of ivermectin in children weighing less than 15 kg. The data provides limited but
encouraging evidence that ivermectin is safe and well-tolerated in small children weighing
less than 15 kg. The ivermectin tolerability and safety profile in children weighing less than
15 kg is similar to that in heavier individuals. Further investigation is warranted through
well-designed clinical trials in children weighing less than 15 kg with the objective of optimiz-
ing dosing and characterizing the safety profile the prescribing restriction in young children
can be lifted.
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